The TruSight Myeloid Sequencing Panel uses expert-defined content and proven next-generation sequencing (NGS) technology to identify somatic variants in myeloid malignancies.
The panel content was designed by a consortium of recognized experts in blood cancer disorders and targets genes frequently mutated in: